Menu Search
Equities

Achieve Life Sciences Inc

SP4P:FRA

Achieve Life Sciences Inc

Actions
  • Price (EUR)4.58
  • Today's Change-0.105 / -2.24%
  • Shares traded21.00
  • 1 Year change-36.46%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

  • Revenue in USD (TTM)0.00
  • Net income in USD-27.32m
  • Incorporated1995
  • Employees22.00
  • Location
    Achieve Life Sciences Inc22722 29TH DR. SE, SUITE 100SEATTLE 98021United StatesUSA
  • Phone+1 (425) 686-1500
  • Fax+1 (302) 636-5454
  • Websitehttp://achievelifesciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.